214 related articles for article (PubMed ID: 20370447)
1. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.
Garcés EO; Victorino JA; Thomé FS; Röhsig LM; Dornelles E; Louzada M; Stifft J; de Holanda F; Veronese FV
Ren Fail; 2010 Jan; 32(3):320-7. PubMed ID: 20370447
[TBL] [Abstract][Full Text] [Related]
2. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
3. Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter.
Arcangeli A; Rocca B; Salvatori G; Ciancia M; De Cristofaro R; Antonelli M
Thromb Res; 2010 Jul; 126(1):24-31. PubMed ID: 20185164
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
[TBL] [Abstract][Full Text] [Related]
8. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
[TBL] [Abstract][Full Text] [Related]
9. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
Morabito S; Guzzo I; Solazzo A; Muzi L; Luciani R; Pierucci A
J Nephrol; 2003; 16(4):566-71. PubMed ID: 14696760
[TBL] [Abstract][Full Text] [Related]
10. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy.
Vitale C; Verdecchia C; Bagnis C; Ganzaroli M; Giorcelli G; Marangella M
J Nephrol; 2008; 21(2):205-12. PubMed ID: 18446715
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial.
Kozek-Langenecker SA; Spiss CK; Gamsjäger T; Domenig C; Zimpfer M
Wien Klin Wochenschr; 2002 Feb; 114(3):96-101. PubMed ID: 12060975
[TBL] [Abstract][Full Text] [Related]
12. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
[TBL] [Abstract][Full Text] [Related]
13. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
15. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
[TBL] [Abstract][Full Text] [Related]
16. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
[TBL] [Abstract][Full Text] [Related]
18. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
Schiele F; Meneveau N; Seronde MF; Descotes-Genon V; Dutheil J; Chopard R; Ecarnot F; Bassand JP;
Am Heart J; 2010 Feb; 159(2):190-8. PubMed ID: 20152216
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
Naumnik B; Borawski J; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
